Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NTLA) announced significant progress in its clinical programs, notably the initiation of a Phase 1 trial for NTLA-2001, targeting transthyretin amyloidosis (ATTR), with patient dosing expected by year-end 2020. The company also aims to submit IND applications for NTLA-5001 (acute myeloid leukemia) in 1H 2021, and NTLA-2002 (hereditary angioedema) in 2H 2021. Financially, Intellia ended Q3 2020 with $407.9 million in cash, marking a healthy increase from the previous year, despite a net loss of $27.8 million. Collaboration revenue rose significantly, driven by the Regeneron partnership.

Intellia Therapeutics (NASDAQ:NTLA) will present its Q3 2020 financial results and operational highlights on November 5, 2020, at 8 a.m. ET. Interested participants can join the call by dialing 1-877-317-6789 in the U.S. or 1-412-317-6789 internationally. A replay will be available post-call on the company's website from 12 p.m. ET the same day. Intellia is focused on developing curative therapeutics using CRISPR/Cas9 technology, aiming to revolutionize medicine by permanently editing disease-related genes with a single treatment.

Intellia Therapeutics (NASDAQ: NTLA) announced the authorization of its Clinical Trial Application to commence a Phase 1 study of NTLA-2001, targeting hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). This therapy, potentially the first curative treatment for ATTR, utilizes in vivo CRISPR/Cas9 technology. The trial aims to assess safety, pharmacokinetics, and efficacy, with expectations to dose the first patient by the end of 2020. Intellia plans to expand the study after determining the optimal dose and further regulatory applications in other countries.

Intellia Therapeutics' co-founder, Dr. Jennifer Doudna, has been awarded the 2020 Nobel Prize in Chemistry for her role in developing the CRISPR/Cas9 genome editing technology, alongside Dr. Emmanuelle Charpentier. This milestone marks the first instance of two women jointly winning this accolade in Chemistry. Intellia’s leadership highlighted the transformative potential of CRISPR/Cas9 in addressing genetic diseases and cancer. The company underscores its commitment to utilizing this groundbreaking tool to develop enduring therapeutic solutions for complex health conditions.

Intellia Therapeutics (NASDAQ: NTLA) has appointed John F. Crowley to its Board of Directors, bringing extensive biotech experience, particularly in rare diseases. Crowley, CEO of Amicus Therapeutics, has a strong track record in transitioning programs from preclinical to clinical stages. His insights as a parent advocate for Pompe disease will be valuable as Intellia embarks on its first clinical trial this year. Meanwhile, Perry Karsen will step down from the board effective December 31, 2020, after five years of significant contributions to the company's growth.

Intellia Therapeutics (NASDAQ: NTLA) will present at Baird’s 2020 Virtual Global Healthcare Conference on September 9, 2020, at 10:50 a.m. ET. The presentation will showcase the company's advancements in CRISPR/Cas9 technology aimed at developing curative therapeutics. A live webcast can be accessed on the company's website, with a replay available for 14 days post-event. Intellia focuses on editing disease-associated genes to treat cancer and immunological diseases, positioning itself as a leader in genome editing.

Intellia Therapeutics (NTLA) has submitted its first regulatory application to the U.K.’s MHRA for a Phase 1 study of NTLA-2001, targeting transthyretin amyloidosis, aiming to dose the first patient by year-end. The company expanded its collaboration with Regeneron, receiving $100 million to co-develop hemophilia treatments. Intellia plans to submit INDs for NTLA-5001 (acute myeloid leukemia) and NTLA-2002 (hereditary angioedema) in 2021. As of June 30, 2020, the company reported a cash position of $436.8 million, enabling operations for at least 24 months.

Intellia Therapeutics (NASDAQ: NTLA) will present its second quarter 2020 financial results and operational highlights in a conference call scheduled for August 6, 2020, at 8 a.m. ET. The company, a frontrunner in genome editing using CRISPR/Cas9 technology, aims to develop curative therapeutics both in vivo and ex vivo. Interested participants can join the call by dialing the provided numbers or access a replay on the company's website later that day. Intellia's commitment to advancing CRISPR technology positions it for significant therapeutic applications.

Intellia Therapeutics (NTLA) has successfully completed an underwritten public offering of 6,301,370 shares at $18.25 per share, raising approximately $115 million in gross proceeds. The offering included the full exercise of an option for an additional 821,917 shares. Goldman Sachs, Jefferies, and SVB Leerink served as joint book-running managers. The shares were offered under a previously filed shelf registration statement, and a final prospectus supplement detailing the offering was filed with the SEC on June 3, 2020.